namitecan
Small moleculeexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2007 (NCT01748019)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- DNA topoisomerase IINHIBITOR
TOP1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- namitecan
- namitecan
- st1968
- st1968
- st1968
- st 1968
- st-1968
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01748019 | Phase 1 | Jun 1, 2007 | Cantonal Hospital of St. Gallen, Leadiant Biosciences, Inc., Southern Europe New Drug Organization (SENDO) |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cantonal Hospital of St. Gallen | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Leadiant Biosciences, Inc. | For profit | 1 | 1 | 1 | 2007 |
| Southern Europe New Drug Organization (SENDO) | Academic/Hospital | 1 | 0 | 1 | 2007 |
3 organizations
Page 1 / 1